- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07869147
Study of ORJ-001 for the Treatment of IPF
A Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability (Part A), and Efficacy (Part B), of ORJ-001 in Patients With Idiopathic Pulmonary Fibrosis (ORBIT-IPF)
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This Phase 2a/2b, randomized, double-blind, placebo-controlled, multicenter study will evaluate the safety, tolerability, and efficacy of ORJ-001 administered subcutaneously twice weekly in adults with IPF. The study consists of two parts. Part A will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of two dose levels of ORJ-001 compared with placebo over 12 weeks of treatment. Data from Part A will be reviewed by an independent Data Monitoring Committee to select the dose for Part B. Participants in Part A will not continue into Part B; Part B will enroll a separate cohort of participants. Part B will evaluate the efficacy of the selected ORJ-001 dose compared with placebo, with the primary efficacy endpoint being change from baseline in forced vital capacity (FVC) at Week 12. Secondary and exploratory assessments include percent predicted FVC, time to acute IPF exacerbation, respiratory hospitalization or death, patient-reported outcomes, pharmacokinetics, and biomarkers of fibrosis. Adults aged 40 years or older with confirmed IPF and adequate pulmonary function who are receiving stable antifibrotic standard-of-care therapy, or who have previously discontinued such therapy due to tolerability or lack of response, may be eligible to participate.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Clinical Trials
- Telefonnummer: 1 (832) 400-6140
- E-mail: clinicaltrials@oorjabio.com
Undersøgelse Kontakt Backup
- Navn: Clinical Trials
- E-mail: clinicaltrials@oorjabio.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- University of Alabama at Birmingham
-
Ledende efterforsker:
- Tejaswini Kulkarni, MD
-
-
Florida
-
Doral, Florida, Forenede Stater, 33172
- Rekruttering
- Innova Pharma Research, LLC
-
-
Pennsylvania
-
DuBois, Pennsylvania, Forenede Stater, 15801
- Rekruttering
- Clinical Research Associates of Central PA
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Male or female participants aged ≥ 40 years when signing informed consent
- Non-smoker or ex-smoker who has stopped smoking for > 6 months prior to signing informed consent
- Diagnosis of IPF, as defined by 2022 international guidelines and confirmed by centrally adjudicated finding of a definite or probable UIP pattern on HRCT of the chest. The HRCT may be performed at screening or, if available, a historical HRCT obtained within 12 months from screening may be submitted for central review
- FVC of at least 45% of the predicted value and a DLCO, corrected for the hemoglobin level, of at least 25% and no greater than 90% of the predicted value. Note: Each test (FVC and DLCO) may be repeated once after a minimum of 24 hours if the initial result is deemed unreliable by the investigator
- If receiving SOC antifibrotic therapy, participants must be on a stable regimen of a single approved therapy for at least 60 days prior to the screening visit. Participants who have discontinued SOC antifibrotic therapy due to tolerability or lack of response may be enrolled after at least 30 days of discontinuing the SOC antifibrotic therapy.
- Negative serum pregnancy test in women of childbearing potential at the screening visit
Key Exclusion Criteria:
- Participants who are treatment-naïve with respect to SOC antifibrotic therapies
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial
- Major surgery (including joint surgery) within 8 weeks from screening, or planned major surgery within 4 months following randomization
- Presence of one or more significant concurrent medical conditions that may affect the outcome of the study per investigator judgement
- Participants with relevant airway obstruction, defined as pre bronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) ratio < 0.7 at screening
- Lower respiratory tract infection requiring antibiotics within 4 weeks from screening, or during the screening period (may be rescreened following recovery)
- Acute IPF exacerbation within 3 months from screening, or during the screening period
- Receiving more than 15 mg per day of prednisone during screening
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Part A: ORJ-001 400 mg
Participants receive ORJ-001 400 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (400 mg:200 mg:placebo). |
ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated. Matching placebo administered by subcutaneous injection twice weekly. |
|
Eksperimentel: Part A: ORJ-001 200 mg
Participants receive ORJ-001 200 mg administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Randomization ratio: 3:1:1 (active:active:placebo). |
ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated. Matching placebo administered by subcutaneous injection twice weekly. |
|
Placebo komparator: Part A: Placebo
Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. |
Matching placebo administered by subcutaneous injection twice weekly. |
|
Eksperimentel: Part B: ORJ-001 (Selected Dose)
Participants receive the ORJ-001 dose selected based on Part A safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy data, administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. Participants are randomized 1:1 to ORJ-001 or placebo. |
ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated. Matching placebo administered by subcutaneous injection twice weekly. |
|
Placebo komparator: Part B: Placebo
Participants receive matching placebo administered subcutaneously (SC) twice weekly (BIW) for 12 weeks. |
Matching placebo administered by subcutaneous injection twice weekly. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part A: Safety and Tolerability of ORJ-001: Number of Participants with Treatment-Related Adverse Events (TEAEs)
Tidsramme: From first dose through Safety Follow-up Visit, up to 12 weeks.
|
Number of participants experiencing at least one treatment-emergent adverse event. |
From first dose through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Severity of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: From first dose through Safety Follow-up Visit, up to 12 weeks.
|
Severity of treatment-emergent adverse events as graded according to CTCAE v6.0. |
From first dose through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Systolic Blood Pressure
Tidsramme: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in systolic blood pressure measured in millimeters of mercury (mmHg). |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Body Temperature
Tidsramme: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in body temperature measured in degrees Celsius (°C). |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Heart Rate
Tidsramme: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in heart rate measured in beats per minute (bpm). |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Respiratory Rate
Tidsramme: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in respiratory rate measured in breaths per minute. |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Oxygen Saturation
Tidsramme: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
Change from baseline in oxygen saturation measured as percentage (% SpO₂). |
Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
|
|
Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Corrected QT Interval
Tidsramme: Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
|
Change from baseline in corrected QT interval (QTc) measured by electrocardiogram (ECG) in milliseconds (ms). |
Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
|
|
Part B: Change from Baseline in Forced Vital Capacity (FVC)
Tidsramme: Baseline to Week 12
|
Change from baseline in FVC measured by spirometry at Week 12. |
Baseline to Week 12
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part B: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC%)
Tidsramme: Baseline to Week 12.
|
Change from baseline in percentage of predicted FVC measured by spirometry at Week 12. |
Baseline to Week 12.
|
|
Part B: Time to Acute Exacerbation of IPF, Hospitalization for a Respiratory Cause, or Death
Tidsramme: Up to Week 12.
|
Time, in days, to first occurrence of acute IPF exacerbation, hospitalization for a respiratory cause, or death. |
Up to Week 12.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Oorja Bio Medical Director, Oorja Bio, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ORJ-001-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .